Tactile Systems Technology, Inc. (TCMD)
Largest Insider Buys in Sector
TCMD Stock Price History Chart
TCMD Stock Performance
About Tactile Systems Technology, Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the …
Insider Activity of Tactile Systems Technology, Inc.
Over the last 12 months, insiders at Tactile Systems Technology, Inc. have bought $0 and sold $467,683 worth of Tactile Systems Technology, Inc. stock.
On average, over the past 5 years, insiders at Tactile Systems Technology, Inc. have bought $44,835 and sold $1.96M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,900 shares for transaction amount of $44,835 was made by BURKE WILLIAM W () on 2022‑08‑04.
List of Insider Buy and Sell Transactions, Tactile Systems Technology, Inc.
| 2024-08-12 | Sale | Senior VP, Sales | 1,550 0.0065% | $13.07 | $20,263 | +9.48% | ||
| 2024-05-16 | Sale | Chief Financial Officer | 3,041 0.0129% | $13.68 | $41,590 | -3.22% | ||
| 2024-05-08 | Sale | director | 2,500 0.0107% | $14.06 | $35,150 | -3.90% | ||
| 2024-05-06 | Sale | Sr. VP Mktg & Clinical Affairs | 815 0.0035% | $14.37 | $11,713 | -6.20% | ||
| 2024-02-29 | Sale | President and CEO | 1,396 0.0059% | $15.25 | $21,289 | -7.65% | ||
| 2024-02-29 | Sale | Sr. VP Mktg & Clinical Affairs | 243 0.001% | $15.25 | $3,706 | -7.65% | ||
| 2024-02-27 | Sale | President and CEO | 4,689 0.0196% | $15.60 | $73,148 | -11.52% | ||
| 2024-02-27 | Sale | Sr. VP Mktg & Clinical Affairs | 1,091 0.0045% | $15.58 | $17,001 | -11.52% | ||
| 2024-02-26 | Sale | President and CEO | 6,239 0.0269% | $15.81 | $98,645 | -8.86% | ||
| 2024-02-26 | Sale | Sr. VP Mktg & Clinical Affairs | 2,015 0.0087% | $15.90 | $32,049 | -8.86% | ||
| 2024-02-23 | Sale | President and CEO | 5,378 0.0215% | $14.85 | $79,853 | -10.61% | ||
| 2024-02-23 | Sale | Sr. VP Mktg & Clinical Affairs | 2,249 0.009% | $14.80 | $33,278 | -10.61% | ||
| 2023-08-07 | Sale | President and CEO | 1,062 0.0046% | $20.53 | $21,808 | -31.31% | ||
| 2023-05-12 | Sale | director | 4,400 0.021% | $21.86 | $96,184 | -29.87% | ||
| 2023-05-08 | Sale | Sr. VP Mktg & Clinical Affairs | 786 0.0037% | $18.65 | $14,659 | -18.84% | ||
| 2023-05-08 | Sale | Senior VP, Sales | 550 0.0026% | $18.55 | $10,200 | -18.84% | ||
| 2023-03-01 | Sale | Chief Financial Officer | 1,391 0.0064% | $14.10 | $19,613 | +9.47% | ||
| 2023-02-28 | Sale | President and CEO | 700 0.0033% | $14.56 | $10,189 | +9.86% | ||
| 2023-02-28 | Sale | Chief Financial Officer | 251 0.0012% | $14.58 | $3,660 | +9.86% | ||
| 2023-02-28 | Sale | Sr. VP Mktg & Clinical Affairs | 135 0.0006% | $14.58 | $1,968 | +9.86% |
Insider Historical Profitability
| BURKE WILLIAM W | director | 25273 0.1053% | $15.84 | 1 | 14 | +42.14% |
| SODERBERG PETER H | director | 236450 0.9853% | $15.84 | 1 | 0 | +38.26% |
| Moen Brent | Chief Financial Officer | 48760 0.2032% | $15.84 | 1 | 9 | <0.0001% |
| NIGON RICHARD | director | 16785 0.0699% | $15.84 | 3 | 5 | +21.69% |
| Pegus Cheryl | director | 2184 0.0091% | $15.84 | 1 | 0 | +77.98% |
Institutional Investor Ownership
| First Light Asset Management | $42.93M | 11.12 | 2.64M | -7.62% | -$3.54M | 3.62 | |
| BlackRock | $38.34M | 9.93 | 2.36M | -2.7% | -$1.06M | <0.01 | |
| Cadian Capital Management LP | $31.33M | 8.11 | 1.93M | +10.49% | +$2.97M | 1.11 | |
| The Vanguard Group | $22.48M | 5.82 | 1.38M | +0.97% | +$216,937.51 | <0.0001 | |
| Morgan Stanley | $15.01M | 3.89 | 923,669 | +384.2% | +$11.91M | <0.01 |